300583.SHE Shandong Sito Bio-technology Co Ltd
- Market cap
- CNY 2.07B
- P/E
- 78.0x
- P/B
- 1.18x
- ROE
- 2.5%
- Dividend yield
- 1.34%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300583.SHE undervalued?
Graham number300583.SHE trades 102.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shandong Sito Bio-technology Co Ltd fundamental analysis
No fundamental analysis for Shandong Sito Bio-technology Co Ltd yet.
Shandong Sito Bio-technology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shandong Sito Bio-technology Co Ltd
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, bis-decyl alcohol (BA), neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, 16ß and 16a methyl epoxide, and hexahydro-3a-methyl, as well as androsta-1,4-diene-3,17-di…
Full company profileShandong Sito Bio-technology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shandong Sito Bio-technology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 568M | 786M | 1.05B | 966M | 913M | 1.20B | 1.31B | 1.28B | 971M | 1.02B | 1.16B |
| Gross Profit | 191M | 183M | 264M | 230M | 99.1M | 246M | 261M | 268M | 108M | 153M | 285M |
| Operating Income | 114M | 103M | 149M | 67.2M | -186M | 56.0M | 49.2M | 32.7M | -102M | 3.50M | 101M |
| EBITDA | 173M | 170M | 238M | 182M | -14.1M | 219M | 248M | 264M | 102M | 120M | 93.2M |
| Net Income | 101M | 92.0M | 126M | 55.3M | -180M | 36.2M | 42.0M | 45.6M | -88.8M | -73.1M | 44.0M |
| EPS | 0.79 | 0.55 | 0.74 | 0.33 | -1.05 | 0.21 | 0.24 | 0.25 | -0.47 | -0.39 | 0.23 |
| Balance Sheet | |||||||||||
| Total Assets | 936M | 2.02B | 2.59B | 2.99B | 2.84B | 2.97B | 3.00B | 3.24B | 3.03B | 2.96B | 2.98B |
| Total Liabilities | 333M | 317M | 733M | 1.10B | 1.15B | 1.24B | 1.22B | 1.17B | 1.14B | 1.16B | 1.18B |
| Shareholders' Equity | 580M | 1.69B | 1.81B | 1.83B | 1.64B | 1.68B | 1.72B | 2.01B | 1.84B | 1.76B | 1.76B |
| Cash & Short-term Investments | 33.5M | 311M | 681M | 387M | 344M | 161M | 188M | 238M | 256M | 295M | 234M |
| Total Debt | 234M | 150M | 495M | 752M | 658M | 671M | 700M | 743M | 722M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 80.1M | 10.9M | -334M | 57.6M | 255M | 227M | 145M | -92.8M | 194M | 159M | - |
| Capital Expenditure | 126M | 75.3M | 221M | 211M | 243M | 389M | 144M | 94.1M | 65.5M | 79.7M | 70.5M |
| Free Cash Flow | -45.7M | -64.4M | -555M | -153M | 12.0M | -162M | 1.66M | -187M | 129M | 78.9M | 86.5M |
| Ratios | |||||||||||
| ROE | 17.5% | 5.4% | 7.0% | 3.0% | -10.9% | 2.2% | 2.4% | 2.3% | -4.8% | -4.2% | 2.5% |
| ROA | 10.8% | 4.5% | 4.9% | 1.9% | -6.3% | 1.2% | 1.4% | 1.4% | -2.9% | -2.5% | 1.5% |
| Net Profit Margin | 17.8% | 11.7% | 12.0% | 5.7% | -19.7% | 3.0% | 3.2% | 3.6% | -9.1% | -7.2% | 3.8% |
| Debt to Equity | 0.40x | 0.09x | 0.27x | 0.41x | 0.40x | 0.40x | 0.41x | 0.37x | 0.39x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shandong Sito Bio-technology Co Ltd dividends
- Dividend yield
- 1.34%
- Forward dividend
- 0.02 CNY
- Payout ratio
- -
- Ex-dividend date
- Jul 14, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 27.8M | 0.15 | - |
| 2024 | CNY 113M | 0.60 | - |
| 2023 | CNY 32.3M | 0.18 | 70.8% |
| 2022 | CNY 1.60M | 0.01 | 3.8% |
| 2021 | CNY 24.5M | 0.14 | 67.7% |
| 2020 | CNY 5.51M | 0.03 | - |
| 2019 | CNY 15.1M | 0.09 | 27.2% |
| 2018 | CNY 24.8M | 0.14 | 19.6% |
| 2017 | CNY 14.7M | 0.09 | 16.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.6:1 on Aug 25, 2023.
Who owns Shandong Sito Bio-technology Co Ltd
- Insiders 48.84%
- Institutions 2.74%
- Public & others 48.43%
- Shares outstanding 190M
- Free float 108M
Shandong Sito Bio-technology Co Ltd company profile
- Company name
- Shandong Sito Bio-technology Co Ltd
- Ticker
- 300583.SHE
- ISIN
- CNE100002F36
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 990
- Fiscal year end
- December
- Address
- South section of East Outer Ring Road,, Heze, China, 274100
- Phone
- 86 53 0226 3536
- Website
- sitobiotech.com
About Shandong Sito Bio-technology Co Ltd
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, bis-decyl alcohol (BA), neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, 16ß and 16a methyl epoxide, and hexahydro-3a-methyl, as well as androsta-1,4-diene-3,17-dione and estra-4,9-diene-3,17-dione. It also provides APIs for animal health, including neomycin sulfate and tylosin tartrate. Shandong Sito Bio-technology Co., Ltd. was founded in 2002 and is based in Heze, China.
Shandong Sito Bio-technology Co Ltd management
4- Mr. Qi MiChairman & GM · born 1990
- Mr. Fuwen LiChief Financial Officer · born 1976
- Ms. Lu LiDeputy GM, Board Secretary & Director · born 1977
- Yong Hong WangAccounting Supervisor